Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danuglipron DDI Study with Atorvastatin, Midazolam, and Oral Contraceptives
NCT05093205Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of danuglipron in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Pfizer. Primary endpoints: Area Under the Concentration-time Curve From Time 0 to Infinity for Atorvastatin, Area Under the Concentration-time Curve From Time 0 to Infinity for Midazolam and 2 more. Started Oct 2021; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05093205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093205.